دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Current challenges of diabetes and metabolic disorders in China
Linong Ji MD,Â
doi : 10.1111/dom.15048
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: An analysis using national cross-sectional data
Chu Lin MD, Xingyun Zhu MD, Ruoyang Jiao MD, Xiaoling Cai MD, Suiyuan Hu MD, Fang Lv MD, Wenjia Yang MD, Zonglin Li MD, Linong Ji MD,Â
doi : 10.1111/dom.15029
Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review
Ran Lu MD, Ye Liu MD, Tianpei Hong MD,Â
doi : 10.1111/dom.15014
Metabolic and bariatric surgery in China: A summary of the Greater China Metabolic and Bariatric Surgery Database and comparison with other international registry databases
Peirong Tian MD, Jing Fu MD, Mengyi Li MD, Yang Liu MD, Shibo Bian MD, Meng Zhang RN, Jia Liu RN, Lan Jin MD, Zhongtao Zhang MD, Peng Zhang MD,Â
doi : 10.1111/dom.15012
To summarize the Greater China Metabolic and Bariatric Surgery Database (GC-MBD) and to compare patient characteristics and different procedures performed with data from published reports from other international bariatric surgery registries.
Association between stress hyperglycaemia and in-hospital cardiac events after coronary artery bypass grafting in patients without diabetes: A retrospective observational study of 5450 patients
Xiaojue Li MD, Xiaopei Hou MD, Heng Zhang MD, Xin Qian MD, Xinxing Feng MD, Na Shi MD, Rong Guo MD, Hansong Sun MD, Wei Feng MD, Wei Zhao PHD, Guangwei Li MD, Zhe Zheng MD, Yanyan Chen MD,Â
doi : 10.1111/dom.15013
To investigate the impact of stress hyperglycaemia (SH) on in-hospital adverse cardiac events after coronary artery bypass grafting (CABG) in patients without diabetes.
Burden of liver complications related to non-alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019
Huixin Liu PhD, Jinlei Qi PhD, Jia Yang MD, Feng Liu PhD, Xiaohe Li MD, Peng Yin PhD, Lijun Wang MD, Zhisheng Liang BS, Lai Wei MD, Huiying Rao MD, Maigeng Zhou PhD,Â
doi : 10.1111/dom.15010
Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes
Xueyuan Guo PhD, Caihua Sang PhD, Ribo Tang PhD, Chenxi Jiang PhD, Songnan Li PhD, Nian Liu PhD, Deyong Long PhD, Xin Du PhD, Jianzeng Dong PhD, Changsheng Ma PhD,Â
doi : 10.1111/dom.15043
Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
Roy Rasalam MBBS, Sarah Abdo MBBS, Gary Deed MBBS, Richard O'Brien MBBS, Jane Overland PhD,Â
doi : 10.1111/dom.14953
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review
John S Pemberton BSc, Emma G Wilmot PhD, Katharine Barnard-Kelly PhD, Lalantha Leelarathna PhD, Nick Oliver FRCP, Tabitha Randell MD, Craig E Taplin FRACP, Pratik Choudhary FRCP, Peter Adolfsson PhD,Â
doi : 10.1111/dom.14962
Oral insulin: A history of ambition, failure and data torturing
Tim Heise MD, Leona Plum-Mörschel MD, Eric Zijlstra PhD,Â
doi : 10.1111/dom.14984
Oral insulin (ORMD-0801) in type 2 diabetes mellitus: A dose-finding 12-week randomized placebo-controlled study
Roy Eldor MD, Bruce H. Francis MD, Alexander Fleming MD, Joel Neutel MD, Kenneth Homer MS, Miriam Kidron PhD, Julio Rosenstock MD,Â
doi : 10.1111/dom.14901
Safety and efficacy of an oral insulin (Capsulin) in patients with early-stage type 2 diabetes: A dose-ranging phase 2b study
Roger R. C. New PhD, Sukumar Ramanujam B. Tech(chem), Varsha Chaudhari M. Pharm, Michal Bogus M. Sc(Biotech), Glen N. Travers B. Com, Gajanan Namjoshi MD,Â
doi : 10.1111/dom.14922
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Joseph Azuri MD, Ariel Hammerman PhD, Enis Aboalhasan BA, Ben Sluckis MD, Ronen Arbel PhD,Â
doi : 10.1111/dom.14940
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies
Ildiko Lingvay MD, Alice YY. Cheng MD, Joshua A. Levine MD, Elisa Gomez-Valderas MSc, Sheryl E. Allen MD, Kari Ranta MD, Amelia Torcello-Gómez PhD, Vivian T. Thieu PhD,Â
doi : 10.1111/dom.14943
Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity
Mojca Jensterle PhD, Simona Ferjan PhD, Luka LežaiÄ� PhD, Aljaž SoÄ�an PhD, Katja GoriÄ�ar PhD, Katja Zaletel PhD, Andrej Janez PhD,Â
doi : 10.1111/dom.14944
To evaluate the effect of once-weekly subcutaneous semaglutide 1.0Â mg on the late digestive period of gastric emptying (GE) after ingestion of a standardized solid test meal by using technetium scintigraphy, the reference method for this purpose.
Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study
Paolo Sbraccia MD, Jens Aberle MD, Anne Helene Olsen, Naveen Rathor MD, Atheline Major-Pedersen MD,Â
doi : 10.1111/dom.14945
To assess the in-market use of Saxenda (liraglutide 3.0 mg) and Victoza (liraglutide 1.2 mg/1.8 mg) according to approved indications and posology.
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes
Aditi R. Saxena MD, Stephanie-An Lyle BA, Kaivan Khavandi MD, Ruolun Qiu PhD, Mark Whitlock PhD, William P. Esler PhD, Albert M. Kim MD,Â
doi : 10.1111/dom.14946
Changes in the use of glucose-lowering drugs: A Danish nationwide study
Anton PottegÃ¥rd PhD, Jacob H. Andersen MSc, Jens Søndergaard PhD, Reimar W. Thomsen PhD, Tina Vilsbøll PhD,Â
doi : 10.1111/dom.14947
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906
Arvid Jungnik MD, Jorge Arrubla Martinez MD, Leona Plum-Mörschel MD, Christoph Kapitza MD, Daniela Lamers PhD, Claus Thamer MD, Corinna Schölch PhD, Michael Desch PhD, Anita M. Hennige MD,Â
doi : 10.1111/dom.14948
To report two phase I studies of the novel subcutaneous glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight/obesity.
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial
Ronnie Aronson MD, Ruth E. Brown PhD, Lisa Chu PhD, Harpreet S. Bajaj MD, Hasnain Khandwala MD, Alexander Abitbol MDCM, Nadia Malakieh MD, Ronald Goldenberg MD,Â
doi : 10.1111/dom.14949
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction
YipHan Chin MBBS, Jieyu Lim MBBS, Gwyneth Kong MBBS, Cheng Han Ng MBBS, Rachel Goh MBBS, Mark Muthiah MBBS, Anurag Mehta MD, Bryan Chong MBBS, Chaoxing Lin MBBS, Kai En Chan MBBS, William Kong MBChB, Kian Keong Poh MBBChir, Roger Foo MBBS, Ping Chai MBBS, Tiong-Cheng Yeo MBBS, Adrian F. Low MBBS, Chi Hang Lee MBBS, Huay Cheem Tan MBBS, Mark Yan-Yee Chan MBBS, A Mark Richards MBChB, Poay-Huan Loh MB., BCh., BAO., Nicholas W. S. Chew MBChB,Â
doi : 10.1111/dom.14950
Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study
Àngels Molló MD, Bogdan Vlacho PhD, Mònica Gratacòs MD, Manel Mata-Cases MD, Esther Rubinat PhD, Anna Berenguera PhD, Jordi Real PhD, Ramon Puig-Treserra Biostatistician, Xavier Cos MD, Josep Franch-Nadal MD, Kamlesh Khunti MD, DÃdac Mauricio MD, the INTEGRA research group ,
doi : 10.1111/dom.14951
To evaluate whether a specially designed multicomponent healthcare intervention improves glycaemic control in subjects with poorly controlled type 2 diabetes.
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)
Arihiro Kiyosue MD, Julia P. Dunn MD, Xuewei Cui PhD, Ana Hickey PhD, Tetsuaki Hirase MD, Takeshi Imaoka MD, Robert J. Heine MD,
doi : 10.1111/dom.14952
To assess the safety and efficacy of tirzepatide in people of East Asian descent based on age and body mass index (BMI).
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions
Raul C. Camacho PhD, David Polidori PhD, Tao Chen PhD, Bin Chen PhD, Helen Han Hsu PhD, Bin Gao PhD, Mathieu Marella PhD, Mariusz Lubomirski PhD, Traymon Beavers PhD, Javier Cabrera PhD, Peggy Wong PhD, Andrea R. Nawrocki PhD,Â
doi : 10.1111/dom.14955
To develop an obese, insulin-resistant cynomolgus monkey model of non-alcoholic steatohepatitis (NASH) with fibrosis with a high fat/high cholesterol (HFHC) diet (with or without high fructose) and test its responsiveness to caloric restriction or pioglitazone.
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes
Tim Heise MD, Jenny Chien PhD, John M. Beals PhD, Charles Benson MD, Oliver Klein MD, Julie S. Moyers PhD, Axel Haupt MD, Edward John Pratt MD,Â
doi : 10.1111/dom.14956
To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of basal insulin Fc (BIF; LY3209590), a fusion protein combining a novel single-chain insulin variant together with human IgG2 Fc domain, following single and multiple once-weekly BIF administration.
Association of long-term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study
Ji Hee Yu MD, Regina E. Y. Kim PhD, So Young Park MD, Da Young Lee MD, Hyun Joo Cho MS, Nam Hoon Kim MD, Hye Jin Yoo MD, Ji A Seo MD, Sin Gon Kim MD, Kyung Mook Choi MD, Sei Hyun Baik MD, Chol Shin MD, Nan Hee Kim MD,Â
doi : 10.1111/dom.14958
To investigate the longitudinal changes in brain volume and cognitive function associated with diabetes at midlife, and to examine whether long-term hyperglycaemia, insulin resistance or secretory function is associated with brain atrophy and cognitive decline.
A retrospective analysis of 24-month real-world glucose control for children and adolescents with type 1 diabetes using the MiniMedâ„¢ 670G insulin pump
Maurizio Delvecchio MD, Alessio Galati MD, Claudio Maffeis MD, Stefano Passanisi MD, Riccardo Bonfanti MD, Roberto Franceschi MD, Gianluca Tornese MD, Elena Calzi MD, Angela Zanfardino MD, Giulia Patrizia Bracciolini MD, Elvira Piccinno MD, ISPED Diabetes Study Group ,Â
doi : 10.1111/dom.14934
Current insulin infusion set failure criteria may be too stringent for real-life settings and may skew infusion set failure outcomes in extended-wear infusion set studies
Jasmin R. Kastner PhD, Tina Poettler, Julia Kopanz BSc, MSc, Daniel A. Hochfellner MD, Matt Romey, Petra M. Baumann MA, Douglas Muchmore MD, Paul J. Strasma MBA, Julia K. Mader MD,Â
doi : 10.1111/dom.14935
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence
Fernando Bril MD, Srilaxmi Kalavalapalli MS, Romina Lomonaco MD, Kenneth Cusi MD,Â
doi : 10.1111/dom.14936
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial
Ahmed A. Kolkailah MD, Ildiko Lingvay MD, Idit Dobrecky-Mery MD, Alona Aharonovich PharmD, Jens-Peter David PhD, Cecilie Holse MD, Søren Rasmussen PhD, Darren K. McGuire MD,Â
doi : 10.1111/dom.14941
Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery
Hood Thabit, Womba Mubita, Jose Rubio, Mini Karuppan, Jonathan Schofield, Malgorzata E. Willinska, Roman Hovorka, Lalantha Leelarathna,Â
doi : 10.1111/dom.14942
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial
Hertzel C. Gerstein MD, Emil Wolsk MD, Brian Claggett PhD, Rafael Diaz MD, Kenneth Dickstein MD, Sibylle Hess PhD, Lars Køber MD, Aldo P. Maggioni MD, John J. V. McMurray MD, Jeffrey L. Probstfield MD, Matthew C. Riddle MD, Jean-Claude Tardif MD, Marc A. Pfeffer MD,Â
doi : 10.1111/dom.14954
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis
Juris J. Meier MD, Lars Bardtrum MSc, Alice Y. Y. Cheng MD, Brian Malling MD, Eduard Montanya MD, Lily Wagner MD, Richard E. Pratley MD,Â
doi : 10.1111/dom.14957
Sodium-glucose cotransporter-2 inhibitor prescribing practices
Chris Alcorn DO, Prathayini Subarajan DO, Aditya Kesari DO, Marie Lockhart PhD, Daryl Cottrell MD, Kim Jordan MD,Â
doi : 10.1111/dom.14931
